0
Prelude Therapeutics Banner Image

Prelude Therapeutics

  • Ticker
    Exchange
  • Industry Biotechnology More
  • Sector Healthcare More
Prelude Therapeutics Logo Image
  • 51-200 Employees
  • Based in Wilmington, Delaware
Prelude Therapeutics is a clinical-stage precision oncology company developing innovative drug candidates targeting critical cancer cell pathways. Prelude’s diverse pipeline is comprised of highly differentiated, potentially best-in-class and first-in-class proprietary small molecule compounds aimed at addressing clinically validated pathways for cancers with selectable underserved patientsMore. Prelude’s pipeline includes four candidates currently in clinical development: PRT1419, a potent, selective inhibitor of MCL1, PRT2527, a potent and highly selective CDK9 inhibitor, PRT3645, a next-generation CDK4/6 inhibitor, and PRT3789 a first-in-class SMARCA2/BRM protein degrader.
Prelude Therapeutics

Most Recent Annual Report

Prelude Therapeutics
MOST RECENT 2022 Annual Report and Form 10K

Older/Archived Annual Reports

Prelude Therapeutics Logo Image

Rate This Report

Your vote helps our reports be more useful
Rating Saved!

Thank you for your feedback!